Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David W Cescon

Showing results (101-110 of 133) with videos related to

Pageof 14
Sort By:
Current Oncology (Toronto, Ont.)|February 26, 2026
Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HR+/HER2- Metastatic Breast Cancer 2025Katarzyna J Jerzak, Aalok Kumar, Jean-François Boileau, et al.
Nature Genetics|August 30, 2016
Noncoding somatic and inherited single-nucleotide variants converge to promote ESR1 expression in breast cancerSwneke D Bailey, Kinjal Desai, Ken J Kron, et al.
JCO Precision Oncology|April 26, 2023
Association Between Biomarkers and Clinical Outcomes of Pembrolizumab Monotherapy in Patients With Metastatic Triple-Negative Breast Cancer: KEYNOTE-086 Exploratory AnalysisSherene Loi, Roberto Salgado, Peter Schmid, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 17, 2025
KEYLYNK-009: Pembrolizumab Plus Olaparib in Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer and Clinical Benefit From First-Line Pembrolizumab Plus ChemotherapyHope S Rugo, David W Cescon, Mark E Robson, et al.
Science Translational Medicine|November 17, 2021
Assessing therapy response in patient-derived xenograftsJanosch Ortmann, Ladislav Rampášek, Elijah Tai, et al.
Current Oncology (Toronto, Ont.)|May 26, 2026
Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with Triple Negative Breast Cancer in Both the Early and Metastatic Setting 2025Christine Simmons, Omar F Khan, Christine Brezden-Masley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 12, 2024
Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: Primary Results From TROPION-Breast01Aditya Bardia, Komal Jhaveri, Seock-Ah Im, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2016
BRM Promoter Polymorphisms and Survival of Advanced Non-Small Cell Lung Cancer Patients in the Princess Margaret Cohort and CCTG BR.24 TrialGeoffrey Liu, Sinead Cuffe, Shermi Liang, et al.
Cancer Discovery|June 18, 2020
Epigenetic Switch-Induced Viral Mimicry Evasion in Chemotherapy-Resistant Breast CancerGeneviève Deblois, Seyed Ali Madani Tonekaboni, Giacomo Grillo, et al.
NPJ Breast Cancer|October 12, 2019
Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancerDavid B Page, Harry Bear, Sangeetha Prabhakaran, et al.
Pageof 14

Showing results (101-110 of 133) with videos related to

Sort By:
Pageof 14
Current Oncology (Toronto, Ont.)|February 26, 2026
Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HR+/HER2- Metastatic Breast Cancer 2025Katarzyna J Jerzak, Aalok Kumar, Jean-François Boileau, et al.
Nature Genetics|August 30, 2016
Noncoding somatic and inherited single-nucleotide variants converge to promote ESR1 expression in breast cancerSwneke D Bailey, Kinjal Desai, Ken J Kron, et al.
JCO Precision Oncology|April 26, 2023
Association Between Biomarkers and Clinical Outcomes of Pembrolizumab Monotherapy in Patients With Metastatic Triple-Negative Breast Cancer: KEYNOTE-086 Exploratory AnalysisSherene Loi, Roberto Salgado, Peter Schmid, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 17, 2025
KEYLYNK-009: Pembrolizumab Plus Olaparib in Locally Recurrent Inoperable or Metastatic Triple-Negative Breast Cancer and Clinical Benefit From First-Line Pembrolizumab Plus ChemotherapyHope S Rugo, David W Cescon, Mark E Robson, et al.
Science Translational Medicine|November 17, 2021
Assessing therapy response in patient-derived xenograftsJanosch Ortmann, Ladislav Rampášek, Elijah Tai, et al.
Current Oncology (Toronto, Ont.)|May 26, 2026
Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with Triple Negative Breast Cancer in Both the Early and Metastatic Setting 2025Christine Simmons, Omar F Khan, Christine Brezden-Masley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 12, 2024
Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: Primary Results From TROPION-Breast01Aditya Bardia, Komal Jhaveri, Seock-Ah Im, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 10, 2016
BRM Promoter Polymorphisms and Survival of Advanced Non-Small Cell Lung Cancer Patients in the Princess Margaret Cohort and CCTG BR.24 TrialGeoffrey Liu, Sinead Cuffe, Shermi Liang, et al.
Cancer Discovery|June 18, 2020
Epigenetic Switch-Induced Viral Mimicry Evasion in Chemotherapy-Resistant Breast CancerGeneviève Deblois, Seyed Ali Madani Tonekaboni, Giacomo Grillo, et al.
NPJ Breast Cancer|October 12, 2019
Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancerDavid B Page, Harry Bear, Sangeetha Prabhakaran, et al.
Pageof 14